Martin Luther University Halle-Wittenberg, Institute of Medical Immunology, 06112, Halle (Saale), Germany.
Int J Cancer. 2013 Dec 1;133(11):2522-32. doi: 10.1002/ijc.28278. Epub 2013 Jun 14.
The expression of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is deregulated in human cancer cells with tumor inhibiting or promoting functions. Due to less knowledge on the role of UCHL1 in melanoma progression, the expression pattern and function of UCHL1 as well as the deregulated signaling pathways were characterized. A large number of melanoma cell lines, tissue microarrays of melanoma lesions and control tissues were analyzed for UCHL1 expression using PCR, Western blot and/or immunohistochemistry. The analysis revealed that melanocyte cultures, 24 of 331 melanoma lesions, two of 18 short-term cultures and two of 19 melanoma cell lines tested, respectively, heterogeneously expressed UCHL1. The low frequency of UCHL1 expression in melanoma cells was due to gene silencing by promoter DNA hypermethylation. Using different transfection models an enzyme activity-dependent growth promoting function of UCHL1 via the activation of the mitogen-activated protein kinase signaling pathway was found in melanoma cells. Under oxygen stress a dose-dependent effect of UCHL1 was detected, which was mediated by a dynamic modification of the PI3K-Akt signaling. Thus, the aberrant UCHL1 expression in melanoma cells is linked to dynamic changes in growth properties and signal transduction cascades suggesting that UCHL1 provides a novel marker and/or therapeutic target at least for a subset of melanoma patients.
泛素羧基末端水解酶 1(UCHL1)的表达在具有肿瘤抑制或促进功能的人类癌细胞中被失调。由于对 UCHL1 在黑色素瘤进展中的作用知之甚少,因此对 UCHL1 的表达模式和功能以及失调的信号通路进行了表征。使用 PCR、Western blot 和/或免疫组织化学分析了大量黑色素瘤细胞系、黑色素瘤病变和对照组织的组织微阵列,以检测 UCHL1 的表达。分析表明,黑素细胞培养物、331 个黑色素瘤病变中的 24 个、18 个短期培养物中的 2 个和 19 个黑色素瘤细胞系中的 2 个分别不均匀表达 UCHL1。黑色素瘤细胞中 UCHL1 表达的低频率是由于启动子 DNA 超甲基化导致基因沉默。使用不同的转染模型,发现 UCHL1 通过激活丝裂原活化蛋白激酶信号通路具有依赖酶活性的促生长功能。在缺氧应激下,检测到 UCHL1 的剂量依赖性效应,这是通过 PI3K-Akt 信号的动态修饰介导的。因此,黑色素瘤细胞中异常的 UCHL1 表达与生长特性和信号转导级联的动态变化相关,表明 UCHL1 至少为一部分黑色素瘤患者提供了新的标志物和/或治疗靶点。